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ABSTRACT
Background: The majority of adults with persistent asthma have chronically uncontrolled
disease and interventions to improve outcomes are needed. We evaluated the efficacy, feasi-
bility, and acceptability of a multi-component smartphone-telemedicine program (TEAMS) to
deliver asthma care remotely, support provider adherence to asthma management guide-
lines, and improve patient outcomes.
Methods: TEAMS utilized: (1) remote symptom monitoring, (2) nurse-led smartphone-tele-
medicine with self-management training for patients, and (3) Electronic medical record-
based clinical decision support software. Adults aged 18-44 (N¼ 33) and primary care pro-
viders (N¼ 4) were recruited from a safety-net practice in Upstate New York. Asthma con-
trol, quality of life, and FEV1 were measured at 0, 3 and 6months. Acceptability was
assessed via survey and end-of-study interviews. Paired t-test and mixed effects modeling
were used to evaluate the effect of the intervention on asthma outcomes.
Results: At baseline, 80% of participants had uncontrolled asthma. By 6-months, 80% classi-
fied as well-controlled. Improvements in control and quality of life were large (d¼ 1.955,
d¼ 1.579). FEV%pred increased 4.2% (d¼ 1.687) with the greatest gain in males, smokers, and
lower educational status. Provider adherence to national guidelines increased from 43.3% to
86.7% (CI ¼ 22.11-64.55) and patient adherence to medication increased from 45.58% to
85.29% (CI ¼ 14.79-64.62). Acceptability was 95.7%; In follow up interviews, 29/30 patients
and all providers indicated TEAMS worked better than usual care, supported effective self-
management, and reduced symptoms over time, which led to greater self-efficacy and
motivation to manage asthma.
Discussion: Based on these findings, we conclude that smartphone telemedicine
could substantially improve clinical asthma management, adherence to guidelines,
and patient outcomes.
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Under-treatment of asthma, non-adherence, and poor
outcomes persist across the U.S. and globally (1,2).
Individuals’ with uncontrolled asthma have increased
risk of morbidity and mortality, diminished quality of
life, and elevated symptom burden, and ways to
improve clinical care and asthma outcomes are needed
(3). Fundamental to this objective is promoting multi-
level adherence to evidence-based guidelines (4). It is
commonly acknowledged that patients ignore symp-
toms, take medications inconsistently, and have poor
self-management (5,6). However, nonadherence
extends beyond patients. Healthcare providers (HCP)
conduct sub-standard assessments (7), lack familiarity
with guidelines (8), and fail to impart essential self-
management skills (9). Furthermore, healthcare
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systems have limited resources to provide care (e.g.
appointment availability, specialist care), and may be
difficult for some patients to access (9). Cumulatively,
this translates to nonadherence at patient, provider,
and systems levels and a reinforcing cycle of inad-
equate asthma management, with the result that most
adults with asthma have chronically uncontrolled dis-
ease (10,11).
Improving outcomes is undoubtedly challenging in
an era of over-burdened health systems. Physical
access has been increasingly constrained due to
COVID-19 and resources to provide care are limited.
In recent months, telemedicine has been extensively
adopted as a means to deliver care safely and remotely
(12). This is logical, as there is evidence telemedicine
reduces barriers to care, is desirable to patients, and is
associated with good outcomes (13,14). However, evi-
dence of efficacy derives predominantly from com-
puter- and site-based programs (15), or asynchronous
remote monitoring interventions, whereas many tele-
medicine visits are now being conducted via smart-
phone video conferencing to patients at home,
representing a substantial change in application (16).
This shift is due to the fact that smartphones are
more ubiquitous than computers, and smartphone-
telemedicine (i.e. mobile visits) has tremendous poten-
tial to increase both demographic and geographic
reach (17). However, research supporting efficacy of
this approach for asthma management is scarce (18).
Furthermore, while traditional telemedicine has been
shown to improve asthma outcomes in younger
patients (19–21), few interventions have been tested in
adults with asthma or in real-world practice contexts
(22–24). Thus, a sustainable, practice-integrated,
smartphone-telemedicine intervention to improve
asthma outcomes and multi-level adherence (i.e.
patient, HCP, and systems) is greatly needed. We
developed a multi-component smartphone/telemedi-
cine program for adults with asthma (Technology
Enabled Asthma Management System – TEAMS).
TEAMS capitalizes on low-cost electronic medical
record (EMR) and smartphone technology to provide
guideline-based clinical decision support (CDS),
remote symptom monitoring, self-management sup-
port, and convenient asthma follow-up. The purpose
of this study was to evaluate efficacy and acceptability
of the TEAMS smartphone-telemedicine program
when implemented in a real-world clinical practice
context. We hypothesized patients would have
improved asthma outcomes at three- and six-months
as compared to baseline.
Methods
Setting and study sample
This study was approved by the University of
Rochester Institutional Review Board [NCT03648203]
(18,25). Adult patients (n¼ 33) were recruited from a
safety-net practice in NY to participate in a single-
arm study. Eligibility criteria for patients were: (1)
English speaking, (2) with persistent asthma based on
EPR-3 criteria (26), (3) having a smartphone, (4) not
pregnant and (5) without confounding comorbidities
(cardiac, respiratory). Age range was restricted to
younger adults (18–44 years) on the basis smartphone
usage (17). A randomized roster of potential partici-
pants (n¼ 140) and their primary care providers
(N¼ 5) was generated using the EMR. Patients were
recruited by a research assistant (JS) via phone call,
and providers were recruited by personal email from
the primary investigator.
Intervention
Technology Enabled Asthma Management System
(developer JM) is a multi-component program
designed to support predominantly remote primary
care management of asthma, and is the first reported
program of this type. Full details of development have
been published elsewhere (18). Briefly, TEAMS incor-
porates 3 technological components to augment usual
care: (1) smartphone asthma symptom monitoring via
a patient’s personal smartphone and the MyChart
patient portal (Epic EMR), (2) smartphone-based tele-
medicine follow-up and self-management training
(SMT) with a nurse via Zoom video-conferencing,
and (3) guideline-based clinical decision support
(CDS) software in the EMR that calculates asthma
severity, control, and recommended step-wise therapy
based on Expert Panel Report-3 (EPR3) guide-
lines (26,27).
For the intervention, patients were asked to log
asthma symptoms (non-urgent) daily via their smart-
phone, answering questions such as, "Did you have
any symptoms of asthma in the past 24 h?" and "What
was your peak flow today?" Patients were instructed
to call the HCP or seek care for any urgent symptoms
as per routine care.
A nurse interventionist conducted home telemedi-
cine follow-up with the patient every 2-6weeks until
the asthma was well-controlled. Once good control
was achieved, follow-up occurred every 2-3months.
Symptoms recorded by the patient in the EMR were
reviewed prior to the visit. Each video visit included
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assessment of symptoms, lung function (FEV1), and
recent medication use. Using data verified by the
nurse, the CDS tool then calculated a detailed asthma
assessment, including asthma severity, current control,
prescribed step-wise level of therapy, guideline-recom-
mended level of step-wise therapy, dose of inhaled
corticosteroid (low, medium, high, micrograms),
patient adherence to medication, and an appropriate
follow-up plan. An auto-generated progress note was
posted by the nurse in the EMR and shared with the
HCP to support clinical management and e-prescrib-
ing. Patients identified as having uncontrolled asthma
received electronic medication adjustments prescribed
by the HCP. Phone calls to the HCP were used for
urgent follow-up only. Office visits were initiated if
indicated by the CDS, or requested by the HCP,
nurse, or patient. Self-management training (SMT)
occurred at each visit using the Let’s Talk About
Asthma! series for smartphone, which contains 14 sin-
gle-page modules covering pathophysiology, symptom
monitoring, prevention, management, and communi-
cation (28,29). Modules were designed to be covered
at least once, with repetition of modules until mastery
was demonstrated by the patient.
Data collection and measures
Technology set-up and 0-, 3- and 6-months data col-
lection were conducted in participants’ homes by a
trained research assistant (JS; years 2018—2020). Each
patient received $250 for data collection over 6-
months. Demographics and baseline asthma informa-
tion were assessed using smartphone surveys and
chart review. Asthma severity was assessed by fre-
quency of symptoms, nocturnal awakening, activity
limitations, and short-acting beta-agonist (SABA) use,
using EPR3 criteria (27).
Primary efficacy outcomes (0, 3, 6months)
Asthma control was measured using the Asthma
Control Questionnaire (ACQ) (30), a 7-item Likert-
scale ranging from 0-6. Lower scores indicate better
asthma control and a score of 1.5 has a positive pre-
dictive value of 0.88 for uncontrolled asthma (31).
FEV1 was measured at 0, 3, and 6, months, and each
telemedicine visit using an individual Microlife peak
flow meter (PFM) provided to each patient, which are
accurate to within 5% of the reading or ± 0.1 liters
when compared to traditional spirometry (32).
Training in maximal expiration was provided along
with the PFM at the baseline visit. Quality of life
(QoL) was assessed using the Asthma Quality of Life
Questionnaire (AQLQ, 32-item Likert-scale, range 1-7,
higher scores indicate better QoL) (33).
Secondary efficacy outcomes (baseline, end-of-study)
Healthcare utilization, corticosteroid use, prescriptions/
refills, emergency care, and treatment of comorbidities
were assessed via chart review. Emergency care utiliza-
tion was also assessed by self-report to capture out-of-
network visits. Adherence to guideline-based therapy
(patient and provider) was calculated by the CDS tool
during telemedicine visits based on symptoms, medica-
tion, and missed doses.
Usability and Acceptability were measured with the
Usability Satisfaction and Ease of Use Questionnaire
(USE-Q (34)), a 21-item, 7-point Likert scale (range
1-7), with 7 being the most positive possible score.
Usability and acceptability were also assessed via
1:1 interview.
Qualitative interviews
Patient participants engaged in audio-recorded 1:1 inter-
views to explore experiences and perceptions of the
TEAMS program. Interviews lasted about 45min, used
a semi-structured protocol (Appendix A), and were
conducted by a trained older, White female research
assistant (JS) known to patient participants from prior
data collection visits. HCPs participated in 1:1 end-of-
study interviews with the RA (unknown to HCP) to
evaluate their experiences with the TEAMS program.
Feasibility and intervention dose
Intervention dose was calculated as the (a) total num-
ber of mobile visits, (b) average visit duration
(minutes), (c) SMT dose (minutes of training and
modules delivered), and (d) smartphone symptom
monitoring dose (days monitoring was performed).
Scheduling statistics, visit duration, and technical
feasibility data were collected using Redcap surveys
completed by the RN at each visit. SMT and symptom
monitoring dose were measured using the TEAMS
CDS tool. Cost of program implementation was calcu-
lated based on total visits (kept and no-show visits),
time to conduct visits (minutes late, visit time, docu-
mentation, and follow up), median nursing salary
($30/hour) (35) and equipment provided to patients,
excluding cost of research-related incentives ($250).
Data analysis
Statistical analysis
Distributional characteristics of the data were assessed
using descriptive statistics. Missing data were <1%.
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Bivariate correlations were examined between demo-
graphic and outcome variables using SPSS 25. Paired
t-tests were used to compare primary and secondary
outcomes from baseline to end-of-study, and Cohen’s
d was used to evaluate effect size. Independent t-tests
were used to examine change in ACQ, AQLQ and
FEV1%pred by gender, smoking status, comorbid men-
tal illness, and ANOVA was used to compare out-
comes by race/ethnicity and educational level. To
confirm the t-test results, linear mixed-effects model-
ing was conducted using R statistical software to
evaluate if ACQ, AQLQ, and FEV1%pred changed over
time while controlling for demographic- and health-
related factors (age, gender, race/ethnicity, income,
smoking status, and education).
Qualitative analysis
Transcribed interviews were analyzed using a consensus
approach (JM, JD, KT, AP) and Nvivo12 software (36).
Traditional content analysis techniques were used to
analyze data for patterns of symptoms and self-man-
agement responses (37). Descriptive coding was used to
explore perceptions and experiences with the TEAMS
program (provider and patient), and pattern coding
was used to further develop the themes and clarify con-
cepts (38). Structured memos, member checking, and
peer-debriefing were used to maximize validity (39).
Results
Demographics
Of 140 patients, 65 were reached and screened by phone:
38 were eligible, 1 declined (too busy) and 4 were lost to
contact after screening. Thirty-three provided informed
consent. Three females dropped out after consenting (2
Black, 1 White). One dropped out prior to intervention
due to anxiety, one during the intervention due to time
burden, and one was unenrolled by the healthcare pro-
vider (HCP) due to suicidal ideation. All others received
the intervention and completed the full study (n¼ 30).
Of the five HCP solicited by email, 4 responded, con-
sented, and participated (80%). Sample characteristics are
shown in Tables 1 and 2. Patient participants (N¼ 30)
were predominantly minority (80%), employed, single,
and lower socioeconomic status.
Efficacy
Most patients had uncontrolled asthma at baseline
(80%, defined as ACQ > 1.50). At 3-months, 70% had
well-controlled asthma, with 80% being well-controlled
at 6-months. Effect sizes for improvements in asthma
control and QoL were large (Table 3) and double to
triple the minimum clinically important difference.
Mean FEV1%pred increased 4.20%. Improvements in
FEV1%pred were greatest for smokers (þ10.27% vs.
nonsmokers þ0.68%, CI ¼ 1.72-17.45), males
(þ11.27% vs. females þ0.11%, CI ¼ 3.62-18.72), and
those with high-school education or less (þ7.94% vs.
any college education 0.071%, CI ¼ 0.20-15.82).
Patients with worse asthma control benefited most,
Table 1. Patient demographics and baseline asthma characteristics.
Patient Demographics (N¼ 30) N (%)







Insurance (public) 23 (76.7%)
Education (Highschool or less) 16 (53.3%)
Marital status (Single) 19 (66.3%)
Transportation (public, no car) 16 (53.3%)
Employed full or part time 19 (63.4%)
Current smoker 11 (36.7%)
Comorbid mental illness 17 (56.7%)
Comorbid substance use disorder 4 (13.3%)
Had asthma related emergency visit past 12months 15 (37.5%)
Satisfied with current asthma care 17 (51.5%)
Average age (years) 32.97 (SD 6.33)
Body Mass Index (chart review) 34.36 (SD 11.29)
Average years with asthma (years) 19.55 (SD 10.17)
Average household Income (in $1,000 USD) 27.53 (SD 13.97)
Patient Smartphone usage
Has cell phone with unlimited data 24 (80.0%)
Uses phone to make video calls 25 (83.3%)
Uses phone to access health information 19 (63.3%)
Uses phone to set health reminders 17 (56.7%)
Ever had trouble keeping phone plan active 9 (30.0%)
Has smartphone available most or all the time 30 (100%)
Ever used phone to access patient portal 22 (73.3%)







Well controlled 2 (6.7%)
Not well controlled 12 (40%)
Very poorly controlled 16 (53.3%)
Notes. aExpert Panel Report 3, guidelines from the National Heart Lung
and Blood Institute (2007).
Table 2. Provider characteristics.
Provider Demographics (N¼ 4)
Sex (female) 4 (100%)
Race/Ethnicity, White 3 (75%)
Race/Ethnicity, Asian 1 (25%)
Role, MD 1 (25%)
Role, NP 2 (50%)
Role, PA 1 (25%)
Average age (years (SD)) 36.50 (SD 15.33)
Average years in current professional role (SD) 3.63 (SD 3.59)
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with a strong correlation between baseline ACQ and
improvement in symptoms by end-of-study (r¼-0.82,
p< 0.001). There were no other significant differences
in intervention effects based on gender, smoking status,
education, race/ethnicity, or presence of comorbid
mental illness. Improvement in QoL was strongly asso-
ciated with improved control (r¼ 0.80, p< 0.001) but
not with FEV1%pred (r¼ 0.087, p¼ 0.648). The linear-
effects models broadly confirmed the t-test results for
the outcomes: with statistical significance, ACQ
decreased over time, and both AQLQ and FEV1%pred
increased over time, indicating better asthma control,
quality of life, and pulmonary function.
Adherence to guideline-based therapy, Table 3
HCP adherence to EPR3 guidelines increased signifi-
cantly (þ1.367 steps, SD ¼ 1.377), with 86.7% of
prescribed therapy matching the EPR3-recommenda-
tions by end-of-study vs. 43.3% at baseline (CI ¼
22.11–64.55). Patient adherence to control medication
increased from 45.58% to 85.29% (CI ¼ 14.79–64.62).
Preventive visits for asthma and treatment of related
comorbidities increased significantly in the year follow-
ing start of intervention as compared to the year prior.
Emergency care utilization decreased marginally, how-
ever, use of oral corticosteroids remained unchanged.
Feasibility and intervention dose, Table 4
Nearly 38% of visits occurred after-hours or on week-
ends, with 93.2% of telemedicine visits having no dis-
ruptive technical issues. On average, patients received
five 30-min visits over 6-months. Improvements in
ACQ, AQLQ and FEV1%pred were not significantly
associated with intervention dose, excluding a mar-
ginal association between FEV1%pred and the number
of days home symptom monitoring was performed
(r¼ 0.339, p¼ 0.06). The most commonly repeated
SMT topics were knowing if asthma was controlled,
understanding different medications, demonstrating
correct inhaler technique, and using a PFM. Based on
the average nursing time per visit (44.47min including
visit, documentation and follow up), total visits (148
kept, 47 no-show), median nursing salary ($30/hour) (35)
and equipment provided to patients (PFMþ spacer¼$42),
the cost of delivering the intervention was estimated at
$186.52 per person over 6-months.
Acceptability (HCP), Table 5
HCPs expressed strong satisfaction with the interven-
tion, indicating it saved time and improved workflow,
patient/provider knowledge, communication, and
adherence to medication. HCPs also noted that their
patients increased engagement in care for asthma and
other chronic conditions, a finding that was supported
in patients’ interviews.
Acceptability (patient)
Usability and acceptability were high (mean score ¼
6.61; SD ¼ 0.47). In interviews, many reported the
intervention changed their life, enabling them to take
control of their asthma and be active "like a regular
person" for the first time as adults.
Table 3. Primary and secondary patient outcomes for TEAMS intervention.
Mean (SD) Mean (SD) (d) (p)
Primary Outcomes Baseline(0m) End (6m) Effect Significance
Asthma control (ACQ) 2.157 (0.848) 0.975 (0.111) 1.955 <0.001
Asthma quality-of-life (AQLQ) 4.418 (1.121) 6.019 (0.894) 1.579 <0.001
FEV1 % predicted 81.17% (2.273) 85.37% (2.689) 1.687 0.046
Secondary Outcomes 0months 6months Effect Significance
PCP prescribed therapy aligns with EPR3a 43.3% (50.400) 86.7% (34.574) 1.004 <0.001
PCP prescribed Stepwise level of therapyc 2.23 (1.478) 3.60 (1.423) 0.944 <0.001
Adherence to prescribed controller medicationd 45.58% (41.678) 85.29% (25.091) 1.154 0.004
Mean stepwise level actually taken by patientb 1.90 (1.423) 3.10 (1.348) 0.866 <0.001
Secondary Outcomes Year prior Year following Effect Significance
Prescriptions for controller medication (ICS, LTRA)e 3.39 (4.565) 7.89 (4.254) 1.020 <0.001
Preventive office visits for asthma 0.62(1.115) 1.76 (2.459) 0.597 0.004
Prescriptions for SABAe 4.0(4.329) 6.36 (4.961) 0.507 0.022
Treatment of related comorbiditiesf 0.64 (0.951) 1.18 (1.188) 0.502 0.022
Asthma related emergency visit (chart review) 0.70 (1.236) 0.33 (0.922) 0.339 0.054
Asthma related emergency visit (self-report) 1.36 (2.959) 0.71 (1.384) 0.281 0.288
Systemic corticosteroid use 0.54(0.838) 0.68(2.001) 0.091 0.641
Notes: aTherapy prescribed by PCP is appropriate for level of asthma severity based on EPR3 stepwise treatment recommendations (binary). bStepwise
level of therapy actually used by the patient accounting for medication adherence; cStepwise level according the EPR3 guidelines. eShort acting beta
agonist (SABA) and controller therapy (ICS¼ Inhaled corticosteroids, LTRA¼ Leukotriene receptor agonists) measured as months of coverage; fPCP initi-
ated treatment of related comorbidities : rhinitis, allergies, obesity, esophageal reflux, tobacco dependence, counted once per diagnosis.
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Overview of qualitative themes (patient)
Nine themes were seen across patient interviews.
Nearly all (29/30) reported that: (1) TEAMS worked
better for managing asthma than usual care, and (2)
greater physical, social and emotional support to man-
age asthma along with (3) internalized self-manage-
ment knowledge led to (4) changes in self-management
behaviors, which (5) dramatically reduced symptoms
over time. When participants saw that self-management
changes alleviated symptoms, then they experienced (6)
greater self-efficacy; (7) changed beliefs about asthma;
and had (8) greater motivation to manage asthma.
However, many indicated that (9) ongoing challenges
remain. Delineation of these themes and supporting
coding schema are presented in Figure 1 with illustra-
tive quotes of individual experiences in Table 6. Key
points are described below.
Theme 1: This works. Participants indicated
TEAMS was "better than the doctor" because it was
more comfortable (i.e. visits could be done from home
with less stress), convenient (flexible, no lost work or
travel time), effective, and personal. In particular, par-
ticipants reported feeling connected to the nurse
because of being "face-to-face" via video conferencing,
whereas in office visits a provider often faces a com-
puter. For example:
P13: Being face to face, there’s more of a connection.
You feel like the person’s listening - they’re actually
looking at you.
Theme 2: Greater support—"Someone cares."
Having a nurse who transparently cared, initiated
regular asthma follow up, was easily accessible, and
assisted with medication management, changed partic-
ipants willingness to engage in preventive care. This is
evident in the following quote:
P9: There was no space for me giving me up—I had
help and support right there. … Having someone
[care]—that helped me to care about me.
Being in the program not only made participants
feel supported by the nurse, but also enabled them to
self-advocate for their asthma needs and develop sup-
portive relationships with family, friends, and HCPs.
As one man explained, "It helps me to get the support
I need not just from my primary care physician, but
people around me." (P17). For many, support
included facilitating access to effective controller
medication (i.e. medication/dose adjustments), which
often required multiple attempts:
P24: We found [medication] that worked. You didn’t
just say, “okay, just give it more time.” The
symptoms weren’t [controlled] and you stayed on it
and made me feel like my health mattered. …
Theme 3: Internalized knowledge from self-man-
agement training (SMT).
Many participants indicated the biggest "eye opener"
was realizing uncontrolled asthma causes remodeling
(i.e. "scars your lungs"). As one woman remarked,
"People don’t know about scarred tissue in their lungs
if they don’t take the preventive [medication], or what
the long-term effect is. They just think it’s shortness of
breath, like I did." (P10). Others commented similarly,
indicating that this "scary" information caused them to
be more aware and less accepting of symptoms.
P4: "I realized uncontrolled my asthma was scarring
my lungs, and that’s not good—things that I didn’t
pay attention to [before], now I’m mindful of
those symptoms."
Other key capabilities included being able to differ-
entiate asthma symptoms (vs. cold), understanding
differences between control vs. rescue medication,
using a spacer, knowing when an inhaler is running
out, and being able to manage an asthma attack.
Table 4. Feasibility and intervention dose.
Scheduling and Technical data N (%)
Visits kept as originally scheduled 148/277 (53.4%)
Rescheduled by text message 81/277 (29.2%)
No show 47/277 (17.0%)
Visits occurred on weekend 26/148 (12.8%)
Visits occurred after 5 PM 39/148 (25.7%)
Visits without any Audio/Visual problems 109/148 (73.6%)
Visits with major Audio/visual problems 10/148 (6.8%)
Smartphone telemedicine visits dose Mean (SD)
Total smartphone visits per patient 5 (2.04)
Minutes late to smartphone visit 6.37 (10.68)
Visit duration (minutes) 26 (11.39)
Documentation and follow up time per visit (minutes) 12.05 (13.28)
Total nursing time per visit (minutes) 44.47 (21.67)
CDSS recommended asthma follow up interval (weeks) 3.67 (2.49)
Self-management training (SMT) dose Mean (SD)
Total minutes of SMT (range 33-177) 80.50(42.467)
Specific SMT modulesa
Module 3: Is your asthma controlled? 4.10 (1.626)
Module 4: Different types of asthma medications 3.40 (1.276)
Module 8: How to take puffer and powder inhalers 3.37 (1.608)
Module 9: Why you should use a spacer 2.90 (1.242)
Module 10: Measure your lung function (PFM) 2.73 (1.015)
Module 15: Smoking cessation strategies (smokers) 2.45 (1.572)
Module 2: Uncontrolled asthma can scar your lungs 2.30 (0.988)
Module 11: Asthma triggers and what to do 2.13 (1.655)
Module 5: Know the symptoms of asthma 2.07 (1.230)
Module 1: What is asthma? 1.93 (0.82)
Module 6: Guidelines for treating an asthma attack 1.73 (1.337)
Module 7: Life threatening symptoms 1.67 (1.322)
Module 13: Keeping track of symptoms 1.60 (1.429)
Module 12: Managing exercise asthma 1.27 (1.437)
Module 14: Action plans 0.10 (0.409)
Smartphone symptom monitoring dose Mean (SD)
Symptom/PEF tracking (# of days recorded over 6months) 23.73 (38.403)
Notes. aAverage number of times each module was delivered to
each patient.
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Table 5. Key themes and quotes from end of study interviews with Healthcare Providers (N¼ 4) exploring perceptions of the
TEAMS smartphone-telemedicine program for adults with asthma.
PERCPETION OF TEAMS
TELEMEDICINE PROGRAM
 More efficient process
 Reduced barriers to care for
vulnerable population
 Better educated HCP
 Better educated patient
 Better patient outcomes
MD: it’s all been positive… one patient I had never met before but her pulmonary function testing was really
poor and TEAMS was working on escalating her step wise treatment… so when she came to see me she
was already doing a lot better… . we were able to work behind the scenes to figure out what worked …
so, I didn’t have to see her in clinic, change her meds, send her out, and then have her come back in—that
can be really hard for patients to come in repeatedly. it’s hard for our patient population to make it to
appointments with social determinants of health causing barriers… so I really appreciate the TEAMS
program
NP1: It’s a great program – I’d get a message in my inbox with the record that told me that a patient was
enrolled and their level of asthma control. And it was pretty easy to read and assess how the patient was
doing, even if I hadn’t met them before.
NP2: The patients that went through the program that I touched, they all got better… and they showed up to
their appointments. One patient, he was very excited. Now, he can tell me what his pulmonary functions
test, and he can tell me the impact of his smoking, and how it changed his asthma when he stopped and
when he started again – he really understood what was going on.
PA: I loved it. [The telemedicine nurse] would send me an encounter describing what she did, and follow up,
and she would ask, “Can you prescribe meds if you agree?” So, we would get things moving, and then the
patient would come and see me [in the office], and we would kind of go through with how the changes are
helping or not helping. It actually taught me a lot about titration and protocols for asthma. It not only
helped the patient, but it helped my education as well.
IMPACT ON PATIENT CARE
 Increased adherence to
controller medication




 More engaged in healthcare
MD: I really appreciate that the program teaches compliance and proper usage of inhalers… usually I don’t
have time to do that at clinic… I’m trying to cover a lot of things at once [and] I only see these patients
once in a blue moon
NP1: There was a significant benefit to the patient. Two patients I’m thinking of specifically were just so happy
- they just didn’t know that they could get control, because they hadn’t been involved in care previously. I
think people just accept that they have asthma and don’t realize they can get control.
NP2: Often times our patients end up in the emergency room. We talk to them, they don’t understand what
controller medications are, and that they have to take to keep them out of the emergency room. They
always told me tell me, “these don’t work.” I’m like, “well, they don’t work because you don’t take them
every day.” Somehow, TEAMS was able to get through to them that this was very important stuff. Part of
the problem with controlling asthma is that people don’t have the education and with [this program] they
got the education and understood why they needed to take their inhalers and started to feel better. That
was amazing.
PA: A lot of patients I normally don’t see actually came more because they were feeling better and they had a
connection, so they actually came to their appointments. [We]would talk about their asthma, and they’d be
so happy about it. Like, “I never knew that I wasn’t controlled… now I feel amazing.” And I’m like, “that is
how you’re supposed to feel!” The patients really turned around … I don’t know, they were just different
people. It ties into everything, like their attitude toward medical care. And they want to learn more now,
they want to connect with their health and be more in tune, because they feel better.
IMPACT ON WORKFLOW
 Saves time for HCP
 Saves follow up visits
 Makes job easier
MD: It saved me a lot of time because I wouldn’t have to make an extended visit or 2 appointments… the
population we work with transportation is a big limiting factor, they have to take off work and they can’t
afford to miss a day’s pay, or they have children they need child care for, [so] they miss their appointments.
NP1: it made [my job] really easy. So sometimes we would increase the stepwise therapy before they came
back in, so when you saw the patient, you get like two for one—you see the patient and they’ve already
done what you wanted to do, so they don’t have to then come in for a second visit to reassess. So, it made
it a lot easier, for the patient, but also for me… it saves office visits
NP2: it didn’t really increase my workload at all… the information would be documented in the TEAMS note,
and the patients were actually able to tell me the information, which is huge… I got more information,
what their peak flow was, objective information.
PA: It made it easier. Way less work. The education was the best. Education is the part that takes
longest… understanding how to use their inhaler takes a long time, understanding what asthma is, what
triggers asthma, or what inhaler to use at what times, that takes a long time. And when we’re in a visit,
we’re not just focusing on one thing. Patients are complex and have multiple things… If their diabetes is
uncontrolled [or] they feel bad, they’re going to put asthma to the wayside.
ADVANTAGES, DISADVANTAGES
 Improved access to care
 1:1 education
 Focused on asthma
 Better communication
MD: It’s important to have one-on-one communication [like this] where they’re only focusing on one chronic
medical condition—[patients] need someone monitoring them more carefully than the PCP can. Even in a
private setting, I would see patient 3 or 4 times a year, which is not enough, because asthma changes.
NP1: I found [the telemedicine visit notes] helpful – It’s a lot easier to read it than it is to try to get all that
information out of a patient… it was like somebody did a pre-assessment, and you could just confirm it
with the patient. It made the visit easier, because all the education was done, and education can be the
hardest part, especially in an office setting. I didn’t really see any disadvantages. But, if every single patient
had asthma, I could see it being a little bit more cumbersome.
NP2: I’ve been in practice over 30 years, and asthma has been one of the things that is hardest for the working
poor to control because of their barriers… They can’t get to the doctor, can’t get off work, don’t have extra
time, but they have smart phone… I think it benefits those. This would help reduce admissions and ED
visits.
PA: This was just so helpful - I mean, it would be awesome if we could implement that into primary care. I
wish we could do more telemedicine like this.
JOURNAL OF ASTHMA 7
Many reported the digital PFM was essential to recog-
nizing symptoms, providing reassurance and objective
evidence of progress:
P5: It’s hard for someone who has asthma for so long
that isn’t controlled. You get used to feeling a certain
way [and] it feels normal. The meter lets you know
your airflow is [low]… I didn’t know that it was that
bad… Now, I’m more aware.
Theme 4: Changed self-management. As a result of
increased support and SMT, participants began imple-
menting behavior changes. In general, heightened
awareness of symptoms corresponded with more pro-
active self-management approach:
P17: This helped me to monitor and recognize my
symptoms… I’ve learned a different response. I
know what to do. [Now] I’m taking my preventative
… I don’t tough it out anymore.
For many, establishing an individualized asthma
management routine was key to supporting medica-
tion adherence. As one woman explained, "I was not
good on taking my meds before … now I have an
alarm [and] I’ll take my meds because I got it on the
clock" (P12). Routines included keeping control
inhalers in one or more high-visibility, easy-access
locations, and setting medication reminders on the
smartphone. For example:
P13: I used to put [my inhalers] away and forget
about it, out of sight out of mind. Now I have
medication regiments. If it’s in front of my face, I
remember to do it.
P1: I have one [inhaler] at my toothbrush and one
next to the bed at night. It helps me stay on top of
my medicine.
Figure 1. Thematic map of key findings from exit interviews with patient participants regarding the impact of the TEAMS smart-
phone telemedicine.
8 J. R. MAMMEN ET AL.
Table 6. Quotes from Patient exit interviews (N¼ 30) exploring personal experiences and impact of the TEAMS smartphone-tele-
medicine program for adults with asthma.
P1 (M, AA): it’s a dramatic change … . I went from having [symptoms] three to four times a day to once or twice a week… . I haven’t felt this good in
a long time. I feel like, okay I can do this… before I just postponed taking the medicine and just tried to not do much … now, I take my medicine
like clockwork… . Life has been a lot better.
P3 (M, C): I’ve learned I can control my asthma… [Before] I’d have gone to the doctor to get treated for an infection. [Now] I’ve been telling other
people that have asthma to get on control medicine. My buddy at work has way worse asthma… I talked him into getting control medicine. I’m
coaching my nephew, and my grandmother with COPD how to use her inhalers properly.
P4 (F, AA): I couldn’t run around and play with the kids—now I can. It changed my life, for sure. I went from [having] asthma, terrible, can’t do nothing,
to now my asthma is well-controlled. I don’t have to use my rescue inhaler, I don’t have to worry when I go outside, I really don’t have any
symptoms… . I got a regimen and a reminder in my phone, and I was able to stick with it.
P5 (F, AA): it feels like a doctor visit, but at your leisure, on your own schedule. That was important, otherwise I wouldn’t have had a visit at all. I
haven’t been to a doctor’s office in a long time.
P6 (F, AA): I know how to keep it under control now—that’s a big improvement. Before I was using it [albuterol] every 2 h. [The ICS] helped me a lot,
it’s keeping me from using my rescue inhaler. Even though it irks my nerves and stresses me out keeping track of it, I got myself better. My mom she
wanna join this too.
P7 (M, C): It was a blessing that it was the same person [every time]—It was actually like she was sitting in front of me. The phone reminders were a
very, very big help. [Now] I’m able to actually take a deep breath without freaking choking… [We’ve] gotten my breathing under control. Everybody
who has asthma should be in this program.
P9 (F, AA): What makes a difference with me is doing the peak flow, being able to see how my breathing is … Soon as I see the numbers start to rise,
I felt that I was doing it right. if I see my numbers are up above 430, I’m taking my control medications right, I’m taking everything right. It helps me
keep track… [Before} I was guessing.
P10 (F, AA): [Before] I was not controlled. I wasn’t taking my asthma medicine … I just be brushing it off, like hit and miss…Now I take them
regularly I don’t wake up with barely any symptoms
P11 (M, AA): I’m more of a hands-on person, [I’d rather] go to a building. If I’m not face-to-face, I’m distracted, [and] I didn’t like [doing] the PFM - It
kind of hurts when you blow into it.
P12 (F, AA): I was not good at taking my meds before this program at all … I be thinking I’m fine, but when my doctor listens to me, she be like,“Oh
you’re wheezing pretty bad”, and like, I don’t be really hearing it. I have an alarm now for my meds, and I’ll take it because I got it on the
clock… the [control medicine] really helps.
P13 (F, MR): [Before] I was feeling like I might just die because I couldn’t breathe. I don’t feel like that anymore … . I feel way more confident. [Now] I
walk either in the morning or at night… I couldn’t do that before. Being face to face with somebody [on the smartphone], there’s more of a
connection. You feel like the person’s listening when they’re actually looking at you.
P14 (F, AA): it’s a life changing experience… I’ve never been in control of my asthma like I am now… Before I used to panic, because I have so many
problems breathing, and the pumps didn’t work… . then they showed me the proper way of using the pump and the spacer [and] It works! [Now] I
walk everyday, I play with kids… before it was ‘I can’t play with you, I can’t breathe if I do.’
P15 (M, C): I don’t like going to the doctors [because of] social anxiety and PTSD. [This works] because … it’s through the phone. If I want to, I can set
the phone down and she can’t see me I can’t see her. I think that’s the biggest problem why people don’t have controlled asthma,… no one is
educated. I didn’t know half the shit that [[She]] told me until afterwards.
P16 (F, HL): I learned it was actually asthma symptoms that I was having… I feel more confident knowing more about it… I know what what can
happen if you don’t get any treatments
P17 (M, HL): I’m able to pick up on things that are triggering [symptoms] symptoms I didn’t think were attributed to asthma I come to learn are. … It
causes me to change the way I take my medications… I used to see asthma as a burden and something that would always limit me in some way.
It’s not the case anymore, really.
P18 (F, AA): I was taking the inhaler wrong, using so much clean up products and scented candles… [they] showed me something different that I
should’ve been doing, using the [spacer]so all of it [medication] goes into your lungs… that improved me a whole lot… now I could walk up and
down the stairs, without huffing and puffing! It taught me a whole different route for treating my asthma. That little spacer thing, that little peak
thing… it was very useful. It showed me different numbers of how I was breathing, [if] your lungs wasn’t functioning right
P20 (M, AA): I feel amazing, now… [before] I was all horrible, I was having bad-bad symptoms, and now I feel like I can run around, and do everything
that I really, really want to do.
P21 (F, HL): I can do stuff that I wouldn’t do before. Like, I can go upstairs, downstairs, through the whole house. When I used to do that, I breathed so
hard, sweat so hard, my asthma be bothering me [so] I don’t do them. Now I don’t have the symptoms anymore, It’s amazing. [It’s] a big change in
my life… .I can be happy with myself, instead of being always down.
P22: (F, HL): I didn’t know about the scarring and the swelling. I didn’t know that asthma can do that to your lungs … I’ve been talking to my little
brother and sister about it, because they have asthma [and] they have no idea. I feel like now-since I know how to use [control medication] better
that I am able to take care of my asthma by myself now.
P23 (F, As): I didn’t know untreated asthma can like, really damage your lungs, like really badly. This taught me like, I don’t have to live life miserably
every day. [Before] I thought it was normal. This was perfect, I don’t have time to go to an office to talk to somebody… [with this] I can just video
call [the nurse], it was super easy, and it was really good quality video too
P24 (F, MR): I feel in control, and I actually bragged about this. It makes me feel safe. I actually feel confident. I can pace myself and walk to the
pharmacy, and I don’t feel labored. I don’t feel like my lungs are bleeding, I’m not coughing, throwing up and dizzy. This gave me a blanket of
security.” [Now] I’m not worried if I don’t have my [albuterol] on me… I’m not so scared or worried.
P25 (F, HL): I learned a whole lot from this, and I even taught my husband. He didn’t know things either and he’s asthmatic. Like, I didn’t that the lungs
get swelled up… I’m like “Whoa!.. I need to control my asthma!"… now I’m taking my medication. Before I wasn’t because I feel like it wasn’t
useful, like, “Eh, don’t need it, that’s not doing anything for me.”
P26 (F, AA): [This] changed my outlook on everything. It changed my life. it showed me how to control my asthma and keep me from getting sick and
almost dying. [Now] I can be active more and play with my son and do the things I want to do. It helps you stay focused… [like] how to keep up
with my meds and how to know when [the inhaler] is getting low.
P27 (M, AA): It improved the way I breathe, the way I live. I don’t struggle as much as before. [Asthma] was restricting my life, [this] pushed me to do
better with my own health, give me tools that no one else has given me. [And] it was convenient. I don’t have to get up and drive during snowing
weather. It was personable, I really liked that, and it was the same doctor all the time.
P28 (M, MR): My awareness is different. how I approach my health [is] a more active as opposed to just going with the flow and hoping that you know
my symptoms get better.
(Continued)
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Theme 5: Reduced symptoms. As a result of these
changes, participants indicated they experienced a dra-
matic reduction in symptoms, better quality of life,
increased ability to be physically active, and reduced
anxiety/depression. For example:
P30: Before, I was totally drained, walking around
like an 80-year-old. I couldn’t do anything because of
asthma. [Now] I can breathe. I feel wonderful! I can
do things with my kids, like running around.
P25: I felt better and it helped me calm down
and relax.
Theme 6, 7, and 8: Changed beliefs about asthma,
greater self-efficacy, and greater motivation to man-
age asthma. Experiencing the benefit of effective self-
management was key to changing beliefs about
asthma. Many adults indicated they previously
refrained from taking medications due to misconcep-
tions, fear of dependence, and beliefs that having
symptoms was "normal," but that these belief barriers
changed when they saw the medication worked (i.e.
seeing benefits is believing medication will work).
For example:
P13: I used to think maybe I shouldn’t take [medication]
so often ‘cause I’ll get dependent on it, but now that my
symptoms have started to clear, I don’t feel that way. I
feel like it’s something that prevents it.
P31: I actually see a difference. Before I didn’t, so
what’s the point? Why bother if it’s not doing
anything? Now I can tell—so it’s worth doing.
"Seeing is believing" also impacted approach to and
perspectives of medical care:
P9: Since doing this [my asthma] has progressed
[gotten better], and I’ve actually been going to my
appointments, [Before] I would refuse going to the
doctor, like, “Oh, they’re just going to tell me this is
not right, that’s not right…” But when I seen I was
actually making progress, I have more confidence
going to the doctor.
It is particularly important to note that it was only
after implementing behavior changes and observing a
reduction in symptoms that participants developed
greater confidence in medical treatment and their per-
sonal ability to manage asthma:
P24: [They] found a plan and showed me it can work,
and helped me get into a schedule of seeing it work
and actually putting it into use, and checking up and
following up with me. I have a treatment plan in
place, and I’m confident with my treatment
of asthma.
This translated to increased motivation to sustain
new behaviors, which were now perceived as effective
and beneficial:
P14: Before this, I would go to the doctor and they
told me to do it, but I didn’t ever have nobody to
push me to doing it. Once I did start taking it and I
noticed it was working, I kept doing it.
Lastly, there was an unexpected trickle-down effect
of increased adherence to non-asthma medications,
and a more proactive approach to managing other
chronic conditions:
P17: With me being more on my asthma medication,
I’ve been taking all my other medications too, so it’s
helped me address those issues as well.
Theme 9: Ongoing challenges. While participants
experienced improvements in symptoms and quality-
of-life, ongoing challenges were still present. As seen
in Figure 1, these included trouble accessing medica-
tions, being busy and forgetting to take care of one-
self, and trouble following up with the telemedicine
nurse due to personal or technology issues. Most par-
ticipants felt they would have participated in the pro-
gram regardless of incentives, however others
indicated that incentivizing was essential to their ini-
tial willingness to participate:
P20: a lot of people probably wouldn’t do it [without]
incentive. When I first heard about it, I was like "oh
P29 (M, C): It is so comfortable… I didn’t have to go somewhere for a visit. Like it doesn’t matter if you had pants or shoes on, you didn’t have to be
dressed up to go out… It’s less stress.
P30 (F, MR): I had asthma for 25 years and no one gave me a control inhaler, only albuterol. I was walking around like an 80-year old, exhausted every
day. [Now] I keep up with the control inhaler. I have no symptoms, I feel wonderful, I can run around with my kids. I control my life now, participate
in things, not be sick everyday. I don’t have problems with my asthma anymore.
P31 (M, C): Video chats made all the difference… . I did all my visits on the road. If I have to take a day off work or go without [healthcare], I’ll go
without. [Now] I’m doin’ stuff I didn’t use to [be able] do; movin’ around quicker. I used to ignore my asthma… now, I take the meds and I actually
see a difference… so now it’s worth doin’… .
P32 (F, AA): I feel like my asthma’s under control. [Now] I gotta work with my brother to get his asthma under control. I told him about the inhalers,
how to properly use them. I got him using his because he takes a controlled inhaler so I’ve been helping monitoring him, reminding him to take that
every day [and] use a spacer.
P33 (F, AA): Before, I was scared … I would be taking medicines just to take it… now I know how to take it and what to do… I have asthma but it
doesn’t have me. It doesn’t control my life anymore. I can kick asthma’s butt, but asthma can’t kick mine. I feel so good about myself… This helped
save my life, cause asthma was getting the better of me.
Notes. Quotes are presented sequentially by Participant# (sex, race), excluding non-completers #2, 8, 19 (n¼ 3). F¼ female; M¼male; AA¼African
American; C¼ Caucasian; HL¼Hispanic/Latino.
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yeah, I get paid taking my medicine!" Now that I
know how helpful it was, I will [keep taking it].
Despite challenges, most patients indicated that for
the first time they felt empowered and in control of
their asthma. As one woman expressed so powerfully:
P33: Now, I know what to do. I have asthma, but it
doesn’t have me. It doesn’t control my life anymore. I
can kick asthma’s butt, but asthma can’t kick mine. I
feel so good about myself…
Discussion
Most young-adults with persistent asthma have poor
asthma control under current approaches to care. Our
data suggest smartphone-telemedicine could extend
healthcare reach and improve outcomes with minimal
cost, little workflow disruption, and high patient and
provider satisfaction. These findings are timely given
the increased use of telemedicine in response to the
COVID-19 pandemic, and the absence of best-practice
guidelines for delivering asthma care remotely. This
manuscript provides details on components of high-
quality virtual-care, and compelling preliminary evi-
dence of efficacy, feasibility, and acceptability.
This study utilized a small sample of lower socio-
economic status, urban young-adult patients from a
single hospital-based clinic, and one nurse interven-
tionist. Furthermore, remuneration for patient partici-
pation may have increased participation and
retention, resulting in a positive outcome bias.
Therefore, broader generalizability may be limited.
Nonetheless, it is important to note that most of these
"hard-to-treat" patients had achieved good control by
end-of-study. This could be attributable to several fac-
tors, including increased follow up (40), HCP adher-
ence to stepwise therapy (4), patient adherence to
control medication (41), and training in inhaler tech-
nique (42), which cumulatively resulted in a higher
dose of controller medication being consumed by
patients. A randomized trial with more diverse partici-
pants is indicated to evaluate replicability, generaliz-
ability, and sustainability.
Beyond efficacy and acceptability, other findings
emerged that are worth noting. In particular, self-effi-
cacy is often considered a necessary precursor to
behavior change (8,43,44). In this study, it appeared
that behavior change occurred prior to increasing self-
efficacy, suggesting a cyclical rather than linear rela-
tionship between concepts (45). In other words,
patients who implemented new behaviors and saw evi-
dence of effectiveness developed self-efficacy to con-
tinue behaviors, which is consistent with the common-
sense model for illness self-management (46). The clin-
ical significance is worth considering: changing asthma
management might require a "trial" of new behaviors
to demonstrate benefits, develop confidence, and
increase willingness to sustain change. Simply put,
patients might try it for a period, test it to see if it
works, and take it if there is clear observable benefit.
Unfortunately, healthcare providers often ask
patients to engage in behaviors they have not observed
the value of, as was evident in our baseline interviews.
Thus, effort may be needed to overcome apathy and
reluctance to change, particularly among those diag-
nosed with asthma for an extended time. A simple
application of the "try it—test it—take it" principle
would be to treat aggressively early on. This might
include beginning with higher initial dose of controller
medication to achieve rapid relief of symptoms, and
deescalating to the lowest dose needed to maintain
control, as opposed to the usual practice of increasing
dose when symptom relief is not achieved after weeks
or months.
Second, patients might need more follow-up and
SMT than is common in practice (47). At present,
most SMT is geared toward children/adolescents, care-
givers, or high-risk older-adults (48). However, evi-
dence indicates young-adults have poor understanding
of asthma management and may recall little of asthma
education as children (49). Thus, retraining for these
patients may be warranted. Our participants were
encouraged to follow up every 2weeks until good con-
trol was achieved, amounting to 5 visits and 80min of
personalized SMT, per patient. Based on this, we con-
clude it is unlikely adults can be supported to achieve
good control under current care models. Improving
outcomes will require a system-level commitment to
aggressive follow-up, training, and support to over-
come the many barriers to change.
Conclusion. Good asthma control may be achiev-
able using revolutionary care models (i.e. smartphone
telemedicine with clinical decision support) as an
extension of usual care. This approach can enable
quality care for patients with asthma in a way that
does not increase risk of exposure to infectious dis-
eases, such as COVID-19.
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